
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio is positioned for strong growth with its upcoming clinical data update for prulacabtagene leucel (prula-cel) being evaluated in lupus nephritis and systemic lupus erythematosus, which is expected at the end of this month. With significant efficacy demonstrated in Phase 1 trials, a benign safety profile, and an allogeneic nature giving it an advantage over its competitors, prula-cel has the potential to provide durable therapeutic effects for a broad range of lupus symptoms. Additionally, Adicet Bio's financials show a strong cash position that will sustain the company into the second half of 2027, giving it ample time to continue its research and development efforts. While there are risks associated with clinical trials and financing needs, the current valuation of the company does not fully reflect the potential of its leading product candidate, making it an attractive investment opportunity.
Bears say
Adicet Bio is currently projected to have a total market value of $295M, resulting in a 12-month price objective of $27 per share. However, there are significant risks that could hinder this price target, including negative clinical data, slower-than-expected development timelines, setbacks in later-stage studies, failure to obtain regulatory approvals, lower-than-projected commercial success, and the potential for medium-to-long-term equity dilution. This negative outlook is driven by concerns about the company's ability to successfully develop and commercialize its pipeline products, particularly the potential for setbacks and delays in the clinical development process. Additionally, the company's current market valuation may not accurately reflect these risks and any negative developments could lead to a decline in the stock price.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares